Sphera Funds Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Sphera Funds Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-288,000	Closed	-$4.46M	–	122
2024 Q2	$4.46M	Hold	288,000	–	–	0.61%	52
2024 Q1	$4.59M	Buy	+288,000	New	+$4.34M	0.65%	52
2020 Q3	–	Sell	-730,557	Closed	-$3.38M	–	102
2020 Q2	$3.38M	Buy	+730,557	New	+$3.28M	0.32%	60
2018 Q1	–	Sell	-576,825	Closed	-$2.25M	–	117
2017 Q4	$2.25M	Buy	+576,825	New	+$1.91M	0.26%	86
2016 Q2	–	Sell	-905,000	Closed	-$1.06M	–	98
2016 Q1	$1.06M	Sell	905,000 -550,000	-38%	-$853K	0.23%	79
2015 Q4	$3.56M	Buy	1,455,000 +355,000	+32%	+$1.02M	0.52%	40
2015 Q3	$3.3M	Sell	1,100,000 -100,000	-8%	-$432K	0.42%	50
2015 Q2	$4.96M	Buy	1,200,000 +100,000	+9%	+$399K	0.49%	45
2015 Q1	$4.76M	Buy	1,100,000 +40,000	+4%	+$144K	0.5%	45
2014 Q4	$3.15M	Buy	1,060,000 +374,500	+55%	+$1.03M	0.54%	59
2014 Q3	$2.28M	Buy	+685,500	New	+$1.79M	0.28%	77

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Sphera Funds Management's CPRX Position: Q3 2024 in Review

Sphera Funds Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 288,000 shares — an estimated $4.46M sold.

Sphera Funds Management first reported a position in CPRX in Q3 2014 and held it in 11 quarters. The position peaked at $4.96M in Q2 2015. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

Sphera Funds Management reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
Sphera Funds Management sold 288,000 Catalyst Pharmaceutical shares in Q3 2024, an estimated $4.46M.
Sphera Funds Management first reported a position in Catalyst Pharmaceutical in Q3 2014 and held it in 11 quarters.
Sphera Funds Management's Catalyst Pharmaceutical position peaked at $4.96M in Q2 2015.
316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Sphera Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.